Talaris Therapeutics (NASDAQ:TALS) Given New $23.00 Price Target at Guggenheim

Talaris Therapeutics (NASDAQ:TALSGet Rating) had its price objective lowered by Guggenheim to $23.00 in a report published on Monday, Stock Target Advisor reports. The firm currently has a na rating on the stock.

TALS has been the subject of a number of other research reports. Zacks Investment Research lowered Talaris Therapeutics from a hold rating to a strong sell rating in a research note on Wednesday, March 23rd. Morgan Stanley increased their price target on Talaris Therapeutics from $20.00 to $21.00 and gave the stock an overweight rating in a research note on Wednesday, March 23rd. One research analyst has rated the stock with a sell rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $25.25.

Shares of TALS stock opened at $6.54 on Monday. Talaris Therapeutics has a 52-week low of $5.70 and a 52-week high of $19.82. The firm has a market capitalization of $271.12 million and a PE ratio of -4.39. The stock has a fifty day simple moving average of $8.16 and a two-hundred day simple moving average of $10.75.

Talaris Therapeutics (NASDAQ:TALSGet Rating) last issued its quarterly earnings results on Thursday, March 17th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.04. Equities analysts anticipate that Talaris Therapeutics will post -1.44 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Talaris Therapeutics by 38.3% in the 4th quarter. BlackRock Inc. now owns 2,395,465 shares of the company’s stock valued at $36,626,000 after acquiring an additional 663,633 shares during the last quarter. Norges Bank bought a new position in shares of Talaris Therapeutics in the 4th quarter valued at about $4,168,000. Sectoral Asset Management Inc lifted its holdings in shares of Talaris Therapeutics by 14.5% in the 3rd quarter. Sectoral Asset Management Inc now owns 814,163 shares of the company’s stock valued at $11,040,000 after acquiring an additional 103,163 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Talaris Therapeutics by 102.5% in the 4th quarter. Northern Trust Corp now owns 168,045 shares of the company’s stock valued at $2,569,000 after acquiring an additional 85,058 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Talaris Therapeutics in the 3rd quarter valued at about $1,041,000. Hedge funds and other institutional investors own 74.84% of the company’s stock.

Talaris Therapeutics Company Profile (Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Further Reading

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.